| Sign In to gain access to subscriptions and/or personal tools. |
Cost-Benefit Analysis of a New HEDIS Performance Measure for Pneumococcal VaccinationEpidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, GA fahmed{at}cdc.gov
Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, GA
Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, GA
Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, GA
National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA Objectives. Measurement ofthe quality of care provided by managed care organizations (MCOs) has achieved national prominence, though there is controversy regarding its value. This article assesses the economic implications ofa new Health Plan Employer Data and Information Set (HEDIS®) measure for pneumococcal vaccination. Methods.A Markov decision model, with Monte Carlo simulations, was utilized to conduct a cost-benefit analysis of annual HEDIS-associated interventions, which were repeated for 5 consecutive years, in an average Medicare MCO, using a societal perspective and a 3% annual discount rate. Results.Compared with the status quo, the HEDIS intervention will be cost saving 99.8% ofthe time, with an average net savings of $3.80 per enrollee (95% probability interval: $0.73 $6.87). Conclusions.The new HEDIS measure will save societal dollars. This type of analysis is essential if performance measurement is to become a legitimate part of our health care landscape.
Key Words: cost-benefit cost-effectiveness health maintenance organizations intervention managed care programs outcomes assessment (health care) performance measures pneumococcal vaccine quality of health care
Medical Decision Making, Vol. 22, No. 5 suppl,
S58-S66 (2002) This article has been cited by other articles:
|
|
||||||||||||||


